ES2053757T3 - Composiciones inhibidoras de fosfolipasa a2 y su uso. - Google Patents

Composiciones inhibidoras de fosfolipasa a2 y su uso.

Info

Publication number
ES2053757T3
ES2053757T3 ES88309996T ES88309996T ES2053757T3 ES 2053757 T3 ES2053757 T3 ES 2053757T3 ES 88309996 T ES88309996 T ES 88309996T ES 88309996 T ES88309996 T ES 88309996T ES 2053757 T3 ES2053757 T3 ES 2053757T3
Authority
ES
Spain
Prior art keywords
phospholipase
cell
molecula
pla2
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES88309996T
Other languages
English (en)
Inventor
Saul Yedgar
Arie Dagan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yissum Research Development Co of Hebrew University of Jerusalem
Original Assignee
Yissum Research Development Co of Hebrew University of Jerusalem
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yissum Research Development Co of Hebrew University of Jerusalem filed Critical Yissum Research Development Co of Hebrew University of Jerusalem
Application granted granted Critical
Publication of ES2053757T3 publication Critical patent/ES2053757T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

INHIBIDORES DE LA ACTIVIDAD DE LA FOSFOLIPASA A2 EN LA MEMBRANA DE LA SUPERFICIE DE LA CELULA SU ESTRUCTURA MOLECULAR COMPRENDE UNA MOLECULA DE UN INHIBIDOR PLA2 PERMEABLE A LA CELULA LIGADA COVALENTEMENTE DIRECTA O INDIRECTAMENTE A UNA MOLECULA TRANSPORTADORA ACEPTABLE FISIOLOGICAMENTE QUE ES EFECTIVA PARA INHIBIR LA INTERCALACION EN LA CELULA DE LA MOLECULA INHIBIDOR PLA2 PERMEABLE A LA CELULA, CON LA PREVISION DE QUE ESA FOSFATIDILSERINA NO ESTA LIGADA INDIRECTAMENTE VIA DODECANODIOL DIVALENTE A LA DETRANO HIDRAZINA.
ES88309996T 1987-10-23 1988-10-24 Composiciones inhibidoras de fosfolipasa a2 y su uso. Expired - Lifetime ES2053757T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL8425287A IL84252A (en) 1987-10-23 1987-10-23 Phospholipase inhibiting compositions

Publications (1)

Publication Number Publication Date
ES2053757T3 true ES2053757T3 (es) 1994-08-01

Family

ID=11058262

Family Applications (1)

Application Number Title Priority Date Filing Date
ES88309996T Expired - Lifetime ES2053757T3 (es) 1987-10-23 1988-10-24 Composiciones inhibidoras de fosfolipasa a2 y su uso.

Country Status (8)

Country Link
US (1) US5064817A (es)
EP (1) EP0315349B1 (es)
JP (1) JPH0270703A (es)
AT (1) ATE85223T1 (es)
CA (1) CA1327936C (es)
DE (1) DE3878157T2 (es)
ES (1) ES2053757T3 (es)
IL (1) IL84252A (es)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5925375A (en) * 1987-05-22 1999-07-20 The Liposome Company, Inc. Therapeutic use of multilamellar liposomal prostaglandin formulations
GB9122051D0 (en) * 1991-10-17 1991-11-27 Univ Nottingham Medicines
ES2044781B1 (es) * 1992-04-14 1994-10-01 Menarini Lab Procedimiento para la preparacion de nuevas amidas con accion inhibidora de la fosfolipasa a2
GB2270920B (en) * 1992-09-25 1997-04-02 Univ Keele Alginate-bioactive agent conjugates
EP0658205B1 (en) * 1993-06-25 2000-03-15 Smithkline Beecham Plc Lipoprotein associated phospholipase a2, inhibitors thereof and use of the same in diagnosis and therapy
US6682913B1 (en) 1999-02-03 2004-01-27 Institute For Drug Research Ltd. Microbial process for preparing pravastatin
JP2001131132A (ja) * 1999-08-26 2001-05-15 Kawaken Fine Chem Co Ltd 新規な脂肪酸アルカノールアミド化合物及びそれを含有する界面活性剤組成物
US6420487B1 (en) * 1999-09-08 2002-07-16 Council Of Scientific And Industrial Research Process for the preparation of thermoprecipitating affinity polymers
US7893226B2 (en) 2004-09-29 2011-02-22 Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. Use of lipid conjugates in the treatment of diseases
IL150628A0 (en) * 2000-01-10 2003-02-12 Yissum Res Dev Co Use of lipid conjugates in the treatment of disease
US7101859B2 (en) * 2000-01-10 2006-09-05 Yissum Research Development Company Of The Hebrew University Of Jerusalem Use of lipid conjugates in the treatment of diseases
US7811999B2 (en) * 2000-01-10 2010-10-12 Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. Use of lipid conjugates in the treatment of diseases
US20060189568A1 (en) * 2000-01-10 2006-08-24 Saul Yedgar Use of lipid conjugates in the treatment of infection
US20090325876A1 (en) * 2004-09-29 2009-12-31 Saul Yedgar Use of lipid conjugates in the treatment of diseases associated with vasculature
US7772196B2 (en) * 2000-01-10 2010-08-10 Yissum Research Development Company Of The Hebrew University Of Jerusalem Use of lipid conjugates in the treatment of diseases
US7141552B2 (en) 2000-01-10 2006-11-28 Yissum Research Development Company Of The Hebrew University Of Jerusalem Use of lipid conjugates in the treatment of diseases
US8501701B2 (en) * 2000-01-10 2013-08-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Use of lipid conjugates in the treatment of disease
US7608598B2 (en) * 2000-01-10 2009-10-27 Yissum Research Development Company Of The Hebrew University Of Jerusalem Use of lipid conjugates in the treatment of conjunctivitis
US8076312B2 (en) * 2000-01-10 2011-12-13 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd Use of lipid conjugates in the treatment of disease
US8916539B2 (en) * 2000-01-10 2014-12-23 Yissum Research Development Company Of The Hebrew University Of Jerusalem Use of lipid conjugates in the treatment of disease
US9040078B2 (en) * 2000-01-10 2015-05-26 Yissum Research Development Company Of The Hebrew University Of Jerusalem Use of lipid conjugates in the treatment of diseases of the nervous system
US7393938B2 (en) * 2000-01-10 2008-07-01 Yissum Research Development Company Of The Hebrew University Of Jerusalem Use of lipid conjugates in the treatment of diseases
US8304395B2 (en) * 2000-01-10 2012-11-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Lipid conjugates in the treatment of disease
WO2006054304A2 (en) * 2004-11-17 2006-05-26 Yissum Research Development Company Of The Hebrew University Of Jerusalem Use of lipid conjugates in the treatment of disease
CA2319928A1 (en) * 2000-09-18 2002-03-18 Vasogen Ireland Limited Apoptosis-mimicking synthetic entities and use thereof in medical treatments
TWI281407B (en) 2000-09-18 2007-05-21 Vasogen Ireland Ltd Apoptosis-mimicking synthetic entities and use thereof in medical treatment
US7390795B2 (en) * 2000-12-18 2008-06-24 Pentraxin Therapeutics Limited Treatment and prevention of tissue damage
US8883761B2 (en) * 2001-01-10 2014-11-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Use of lipid conjugates in the treatment of diseases associated with vasculature
GB0100761D0 (en) 2001-01-11 2001-02-21 Biocompatibles Ltd Drug delivery from stents
DE10112825A1 (de) 2001-03-16 2002-10-02 Fresenius Kabi De Gmbh HESylierung von Wirkstoffen in wässriger Lösung
JP2002301352A (ja) * 2001-04-09 2002-10-15 Kawaken Fine Chem Co Ltd １，３−プロパンジオール誘導体含有乳化剤及びそれを含有する乳化組成物
DE10209821A1 (de) 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Kopplung von Proteinen an ein modifiziertes Polysaccharid
DE10209822A1 (de) * 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Kopplung niedermolekularer Substanzen an ein modifiziertes Polysaccharid
US6923961B2 (en) * 2002-04-30 2005-08-02 Fziomed, Inc. Chemically activated carboxypolysaccharides and methods for use to inhibit adhesion formation and promote hemostasis
GB0211136D0 (en) 2002-05-15 2002-06-26 Univ London Treatment and prevention of tissue damage
MXPA05002594A (es) 2002-09-11 2005-05-27 Fresenius Kabi Gmbh Derivados de polipeptidos con hidroxialquilalmidon, especialmente derivados de eritropoyetina con hidroxialquilalmidon.
ATE409048T1 (de) 2002-10-08 2008-10-15 Fresenius Kabi De Gmbh Pharmazeutisch aktive oligosaccharid-conjugate
BR0301513A (pt) * 2003-05-16 2005-03-15 Fundacao De Amparo A Pesquisa Lipossomos, formulações lipossÈmicas, seus usos e processos de obtenção, processo para a produção de soro hiperimune e método de tratamento profilático ou curativo de doenças ou distúrbios passìveis de serem tratados pela administração de soro hiperimune
WO2005014655A2 (en) 2003-08-08 2005-02-17 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein
JP4511470B2 (ja) 2003-10-29 2010-07-28 帝人株式会社 ヒアルロン酸化合物、そのハイドロゲルおよび関節軟骨損傷治療用材料
AR048035A1 (es) 2004-03-11 2006-03-22 Fresenius Kabi De Gmbh Conjugados de almidon de hidroxialquilo y una proteina, preparados por aminacion reductora
US20050244367A1 (en) * 2004-05-03 2005-11-03 Ilypsa, Inc. Phospholipase inhibitors localized in the gastrointestinal lumen
US7808904B2 (en) * 2004-11-18 2010-10-05 Fortinet, Inc. Method and apparatus for managing subscriber profiles
JP5339905B2 (ja) 2005-08-03 2013-11-13 モリア バイオファーマスーティカルズ 嚢胞性線維症における脂質複合体の使用及びその適用
JP5039552B2 (ja) * 2005-08-04 2012-10-03 帝人株式会社 セルロース誘導体
JP4744973B2 (ja) * 2005-08-05 2011-08-10 株式会社トプコン 眼底カメラ
WO2007035116A1 (en) 2005-09-21 2007-03-29 Kode Biotech Limited Cell surface coating with hyaluronic acid oligomer derivative
US7666898B2 (en) 2005-11-03 2010-02-23 Ilypsa, Inc. Multivalent indole compounds and use thereof as phospholipase-A2 inhibitors
US8906882B2 (en) 2005-11-17 2014-12-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Lipid conjugates in the treatment of allergic rhinitis
US8859524B2 (en) 2005-11-17 2014-10-14 Yissum Research Development Company Of The Hebrew University Of Jerusalem Lipid conjugates in the treatment of chronic rhinosinusitis
US20080183282A1 (en) * 2006-03-09 2008-07-31 Saul Yedgar Use of lipid conjugates for the coating of stents and catheters
US8685430B1 (en) 2006-07-14 2014-04-01 Abbott Cardiovascular Systems Inc. Tailored aliphatic polyesters for stent coatings
CA2705785A1 (en) * 2006-11-14 2008-05-22 Saul Yedgar Use of lipid conjugates in the treatment of diseases or disorders of the eye
EP2097086A4 (en) * 2006-11-14 2012-01-11 Yissum Res Dev Co CONTACT LENS COMPOSITIONS
US7713541B1 (en) 2006-11-21 2010-05-11 Abbott Cardiovascular Systems Inc. Zwitterionic terpolymers, method of making and use on medical devices
JP5059787B2 (ja) * 2007-02-06 2012-10-31 帝人株式会社 セルロース誘導体およびその製造方法
JP5242921B2 (ja) * 2007-02-06 2013-07-24 帝人株式会社 ホスファチジルエタノールアミン結合多糖類の製造方法
EP1992364A1 (en) * 2007-05-16 2008-11-19 Biosuma S.r.l. Carboxylated polysaccharides phosphated or bisphosphonated derivatives, optionally cross-linked, and their preparation and biomedical uses
EP2070950A1 (en) 2007-12-14 2009-06-17 Fresenius Kabi Deutschland GmbH Hydroxyalkyl starch derivatives and process for their preparation
AU2010247814B2 (en) * 2009-05-11 2015-08-13 Celsus Therapeutics Plc Lipid-polymer conjugates, their preparation and uses thereof
JP2011099029A (ja) * 2009-11-05 2011-05-19 Teijin Ltd 多糖類誘導体
JP6579470B2 (ja) * 2014-03-06 2019-09-25 キユーピー株式会社 スフィンゴシン１リン酸により修飾されたヒアルロン酸
CN109562098B (zh) * 2016-04-29 2023-04-21 奥菲瑞克斯股份有限公司 用于立即治疗膜翅目注毒和其他因组胺释放引起的病症的pla2抑制剂
CA3209491A1 (en) 2021-03-15 2022-09-22 Saul Yedgar Hyaluronic acid-conjugated dipalmitoyl phosphatidyl ethanolamine in combination with non-steroidal anti-inflammatory drugs (nsaids) for treating or alleviating inflammatory disease

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2247163A1 (de) * 1972-09-26 1974-03-28 Merck Patent Gmbh Traegermatrix zur fixierung biologisch wirksamer stoffe und verfahren zu ihrer herstellung

Also Published As

Publication number Publication date
DE3878157T2 (de) 1993-05-27
DE3878157D1 (de) 1993-03-18
US5064817A (en) 1991-11-12
CA1327936C (en) 1994-03-22
ATE85223T1 (de) 1993-02-15
EP0315349B1 (en) 1993-02-03
JPH0270703A (ja) 1990-03-09
EP0315349A1 (en) 1989-05-10
IL84252A (en) 1994-02-27
IL84252A0 (en) 1988-03-31

Similar Documents

Publication Publication Date Title
ES2035064T3 (es) Aposito para heridas.
MX9405383A (es) Imidazo(4,5-c) piridin-4-aminas.
AR022578A1 (es) Peptidos artificiales que tienen actividad superficial y el uso de los mismos en la preparacion de un tensioactivo artificial
ES2059575T3 (es) Aductos modificados de poliepoxido y polioxialquilen-poliamidas.
ES2146774T3 (es) Polimeros de ioneno que contienen aniones biologicamente activos.
DE59712287D1 (de) VERWENDUNG VON INHIBITOREN DES ZELLULÄREN Na+ /H+ -EXCHANGERS (NHE) ZUR HERSTELLUNG EINES MEDIKAMENTS ZUR NORMALISIERUNG DER SERUMLIPIDE
IT1208603B (it) Procedimento per indurre protoginia in piante di zea mays e relativo zea mays protogino.
ES292544Y (es) Estructura absorbente para comprensa o similar de un solo uso
ATE199016T1 (de) Inhibitoren der dipeptidyl-aminopeptidase vom typ-iv
NL930005I2 (nl) 17 Beta-gesubstitueerde-4-aza-5alfa-androstenonen en gebruik ervan als inhibitoren van 5alfa-reduct ase.
ES2042861T3 (es) Procedimiento para la fabricacion de poliisocianatos modificados.
EE03975B1 (et) Keratinotsüüdi kasvufaktori analoogid
ES2172680T3 (es) Ligante antagonista rar-gamma o agonista rar-alfa como inhibidor de apoptosis.
ATE213952T1 (de) Freisetzung und mobilisierung hämatopoietischer zellen
AR005359A1 (es) Procedimiento para construir obras secundarias y conjuntos de obras secundarias asi obtenidos
DE69332770D1 (de) Sulfonylalkanoylaminohydroxyethylaminosulfamidsäuren verwendbar als retrovirale Proteasehemmer
DK0869970T3 (da) Endothelcelleprolifereringsinhibitor og dens anvendelse
MX9207557A (es) Derivados de acidos benzofuranil- y tiofenilmetiltio-alcanocarboxilicos, procedimiento para su preparacion y medicamentos que los contienen.
ES2100960T3 (es) Estructura proteica de la toxina vegetal gelonina.
ES2051122T3 (es) Quitamanchas liquido que contiene lipasa y uso de dicho quitamanchas.
ES2144626T3 (es) Uso de peptidos de adhesion celular para la modificacion del poder de adhesion de celulas eucarioticas entre si.
DK0563256T3 (da) Anvendelse af værtscelle-phospholipider til inhibering af bakteriekolonisering
ES2035299T3 (es) Un equipo reactivo para su utilizacion en la determinacion de un analito.
DK0793503T3 (da) Anvendelse af hepatocyt-vækstfaktor til inducering af profilerering og differentiering af hemotopoietiske celler
ES2070134T3 (es) Inhibidores de lisil oxidasa.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 315349

Country of ref document: ES